+1 347 708 0418
The Next Generation Antibody Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Next Generation Antibody Therapeutics size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Next Generation Antibody Therapeutics market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Next Generation Antibody Therapeutics market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Antibody Drug Conjugates (ADCs)
Bispecific Antibodies (BsAbs)
Fc Engineered Antibodies
Antibody Fragments and Antibody-Like Proteins (AF & ALPs)
Biosimilar Antibody (Ab) Products
Market segment by Application, can be divided into
Hospitals
Clinics
Others
Market segment by players, this report covers
Pfizer
Roche
Bristol-Myers Squibb
Amgen
AstraZeneca
Bayer
Takeda Pharmaceuticals
Biogen
Seattle Genetics
ImmunoGen
Kyowa Hakko Kirin
Xencor
Dyax Corp
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Next Generation Antibody Therapeutics product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Next Generation Antibody Therapeutics, with revenue, gross margin and global market share of Next Generation Antibody Therapeutics from 2019 to 2021.
Chapter 3, the Next Generation Antibody Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Next Generation Antibody Therapeutics market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Next Generation Antibody Therapeutics research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Product Overview and Scope of Next Generation Antibody Therapeutics
1.2 Classification of Next Generation Antibody Therapeutics by Type
1.2.1 Overview: Global Next Generation Antibody Therapeutics Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Next Generation Antibody Therapeutics Revenue Market Share by Type in 2020
1.2.3 Antibody Drug Conjugates (ADCs)
1.2.4 Bispecific Antibodies (BsAbs)
1.2.5 Fc Engineered Antibodies
1.2.6 Antibody Fragments and Antibody-Like Proteins (AF & ALPs)
1.2.7 Biosimilar Antibody (Ab) Products
1.3 Global Next Generation Antibody Therapeutics Market by Application
1.3.1 Overview: Global Next Generation Antibody Therapeutics Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Next Generation Antibody Therapeutics Market Size & Forecast
1.5 Global Next Generation Antibody Therapeutics Market Size and Forecast by Region
1.5.1 Global Next Generation Antibody Therapeutics Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Next Generation Antibody Therapeutics Market Size by Region, (2016-2021)
1.5.3 North America Next Generation Antibody Therapeutics Market Size and Prospect (2016-2026)
1.5.4 Europe Next Generation Antibody Therapeutics Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Next Generation Antibody Therapeutics Market Size and Prospect (2016-2026)
1.5.6 South America Next Generation Antibody Therapeutics Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Next Generation Antibody Therapeutics Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Next Generation Antibody Therapeutics Market Drivers
1.6.2 Next Generation Antibody Therapeutics Market Restraints
1.6.3 Next Generation Antibody Therapeutics Trends Analysis
2 Company Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Next Generation Antibody Therapeutics Product and Solutions
2.1.4 Pfizer Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Pfizer Recent Developments and Future Plans
2.2 Roche
2.2.1 Roche Details
2.2.2 Roche Major Business
2.2.3 Roche Next Generation Antibody Therapeutics Product and Solutions
2.2.4 Roche Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Roche Recent Developments and Future Plans
2.3 Bristol-Myers Squibb
2.3.1 Bristol-Myers Squibb Details
2.3.2 Bristol-Myers Squibb Major Business
2.3.3 Bristol-Myers Squibb Next Generation Antibody Therapeutics Product and Solutions
2.3.4 Bristol-Myers Squibb Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.4 Amgen
2.4.1 Amgen Details
2.4.2 Amgen Major Business
2.4.3 Amgen Next Generation Antibody Therapeutics Product and Solutions
2.4.4 Amgen Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Amgen Recent Developments and Future Plans
2.5 AstraZeneca
2.5.1 AstraZeneca Details
2.5.2 AstraZeneca Major Business
2.5.3 AstraZeneca Next Generation Antibody Therapeutics Product and Solutions
2.5.4 AstraZeneca Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 AstraZeneca Recent Developments and Future Plans
2.6 Bayer
2.6.1 Bayer Details
2.6.2 Bayer Major Business
2.6.3 Bayer Next Generation Antibody Therapeutics Product and Solutions
2.6.4 Bayer Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Bayer Recent Developments and Future Plans
2.7 Takeda Pharmaceuticals
2.7.1 Takeda Pharmaceuticals Details
2.7.2 Takeda Pharmaceuticals Major Business
2.7.3 Takeda Pharmaceuticals Next Generation Antibody Therapeutics Product and Solutions
2.7.4 Takeda Pharmaceuticals Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Takeda Pharmaceuticals Recent Developments and Future Plans
2.8 Biogen
2.8.1 Biogen Details
2.8.2 Biogen Major Business
2.8.3 Biogen Next Generation Antibody Therapeutics Product and Solutions
2.8.4 Biogen Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Biogen Recent Developments and Future Plans
2.9 Seattle Genetics
2.9.1 Seattle Genetics Details
2.9.2 Seattle Genetics Major Business
2.9.3 Seattle Genetics Next Generation Antibody Therapeutics Product and Solutions
2.9.4 Seattle Genetics Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Seattle Genetics Recent Developments and Future Plans
2.10 ImmunoGen
2.10.1 ImmunoGen Details
2.10.2 ImmunoGen Major Business
2.10.3 ImmunoGen Next Generation Antibody Therapeutics Product and Solutions
2.10.4 ImmunoGen Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 ImmunoGen Recent Developments and Future Plans
2.11 Kyowa Hakko Kirin
2.11.1 Kyowa Hakko Kirin Details
2.11.2 Kyowa Hakko Kirin Major Business
2.11.3 Kyowa Hakko Kirin Next Generation Antibody Therapeutics Product and Solutions
2.11.4 Kyowa Hakko Kirin Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Kyowa Hakko Kirin Recent Developments and Future Plans
2.12 Xencor
2.12.1 Xencor Details
2.12.2 Xencor Major Business
2.12.3 Xencor Next Generation Antibody Therapeutics Product and Solutions
2.12.4 Xencor Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Xencor Recent Developments and Future Plans
2.13 Dyax Corp
2.13.1 Dyax Corp Details
2.13.2 Dyax Corp Major Business
2.13.3 Dyax Corp Next Generation Antibody Therapeutics Product and Solutions
2.13.4 Dyax Corp Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Dyax Corp Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Next Generation Antibody Therapeutics Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Next Generation Antibody Therapeutics Players Market Share
3.2.2 Top 10 Next Generation Antibody Therapeutics Players Market Share
3.2.3 Market Competition Trend
3.3 Next Generation Antibody Therapeutics Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Next Generation Antibody Therapeutics Revenue and Market Share by Type (2016-2021)
4.2 Global Next Generation Antibody Therapeutics Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Next Generation Antibody Therapeutics Revenue Market Share by Application (2016-2021)
5.2 Next Generation Antibody Therapeutics Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Next Generation Antibody Therapeutics Revenue by Type (2016-2026)
6.2 North America Next Generation Antibody Therapeutics Revenue by Application (2016-2026)
6.3 North America Next Generation Antibody Therapeutics Market Size by Country
6.3.1 North America Next Generation Antibody Therapeutics Revenue by Country (2016-2026)
6.3.2 United States Next Generation Antibody Therapeutics Market Size and Forecast (2016-2026)
6.3.3 Canada Next Generation Antibody Therapeutics Market Size and Forecast (2016-2026)
6.3.4 Mexico Next Generation Antibody Therapeutics Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Next Generation Antibody Therapeutics Revenue by Type (2016-2026)
7.2 Europe Next Generation Antibody Therapeutics Revenue by Application (2016-2026)
7.3 Europe Next Generation Antibody Therapeutics Market Size by Country
7.3.1 Europe Next Generation Antibody Therapeutics Revenue by Country (2016-2026)
7.3.2 Germany Next Generation Antibody Therapeutics Market Size and Forecast (2016-2026)
7.3.3 France Next Generation Antibody Therapeutics Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Next Generation Antibody Therapeutics Market Size and Forecast (2016-2026)
7.3.5 Russia Next Generation Antibody Therapeutics Market Size and Forecast (2016-2026)
7.3.6 Italy Next Generation Antibody Therapeutics Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Next Generation Antibody Therapeutics Revenue by Type (2016-2026)
8.2 Asia-Pacific Next Generation Antibody Therapeutics Revenue by Application (2016-2026)
8.3 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region
8.3.1 Asia-Pacific Next Generation Antibody Therapeutics Revenue by Region (2016-2026)
8.3.2 China Next Generation Antibody Therapeutics Market Size and Forecast (2016-2026)
8.3.3 Japan Next Generation Antibody Therapeutics Market Size and Forecast (2016-2026)
8.3.4 South Korea Next Generation Antibody Therapeutics Market Size and Forecast (2016-2026)
8.3.5 India Next Generation Antibody Therapeutics Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Next Generation Antibody Therapeutics Market Size and Forecast (2016-2026)
8.3.7 Australia Next Generation Antibody Therapeutics Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Next Generation Antibody Therapeutics Revenue by Type (2016-2026)
9.2 South America Next Generation Antibody Therapeutics Revenue by Application (2016-2026)
9.3 South America Next Generation Antibody Therapeutics Market Size by Country
9.3.1 South America Next Generation Antibody Therapeutics Revenue by Country (2016-2026)
9.3.2 Brazil Next Generation Antibody Therapeutics Market Size and Forecast (2016-2026)
9.3.3 Argentina Next Generation Antibody Therapeutics Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Next Generation Antibody Therapeutics Revenue by Type (2016-2026)
10.2 Middle East & Africa Next Generation Antibody Therapeutics Revenue by Application (2016-2026)
10.3 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country
10.3.1 Middle East & Africa Next Generation Antibody Therapeutics Revenue by Country (2016-2026)
10.3.2 Turkey Next Generation Antibody Therapeutics Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Next Generation Antibody Therapeutics Market Size and Forecast (2016-2026)
10.3.4 UAE Next Generation Antibody Therapeutics Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Next Generation Antibody Therapeutics Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Next Generation Antibody Therapeutics Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Next Generation Antibody Therapeutics Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Next Generation Antibody Therapeutics Revenue (USD Million) by Region (2016-2021)
Table 5. Global Next Generation Antibody Therapeutics Revenue Market Share by Region (2021-2026)
Table 6. Pfizer Corporate Information, Head Office, and Major Competitors
Table 7. Pfizer Major Business
Table 8. Pfizer Next Generation Antibody Therapeutics Product and Solutions
Table 9. Pfizer Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Roche Corporate Information, Head Office, and Major Competitors
Table 11. Roche Major Business
Table 12. Roche Next Generation Antibody Therapeutics Product and Solutions
Table 13. Roche Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors
Table 15. Bristol-Myers Squibb Major Business
Table 16. Bristol-Myers Squibb Next Generation Antibody Therapeutics Product and Solutions
Table 17. Bristol-Myers Squibb Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Amgen Corporate Information, Head Office, and Major Competitors
Table 19. Amgen Major Business
Table 20. Amgen Next Generation Antibody Therapeutics Product and Solutions
Table 21. Amgen Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 23. AstraZeneca Major Business
Table 24. AstraZeneca Next Generation Antibody Therapeutics Product and Solutions
Table 25. AstraZeneca Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Bayer Corporate Information, Head Office, and Major Competitors
Table 27. Bayer Major Business
Table 28. Bayer Next Generation Antibody Therapeutics Product and Solutions
Table 29. Bayer Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Takeda Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 31. Takeda Pharmaceuticals Major Business
Table 32. Takeda Pharmaceuticals Next Generation Antibody Therapeutics Product and Solutions
Table 33. Takeda Pharmaceuticals Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Biogen Corporate Information, Head Office, and Major Competitors
Table 35. Biogen Major Business
Table 36. Biogen Next Generation Antibody Therapeutics Product and Solutions
Table 37. Biogen Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Seattle Genetics Corporate Information, Head Office, and Major Competitors
Table 39. Seattle Genetics Major Business
Table 40. Seattle Genetics Next Generation Antibody Therapeutics Product and Solutions
Table 41. Seattle Genetics Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. ImmunoGen Corporate Information, Head Office, and Major Competitors
Table 43. ImmunoGen Major Business
Table 44. ImmunoGen Next Generation Antibody Therapeutics Product and Solutions
Table 45. ImmunoGen Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Kyowa Hakko Kirin Corporate Information, Head Office, and Major Competitors
Table 47. Kyowa Hakko Kirin Major Business
Table 48. Kyowa Hakko Kirin Next Generation Antibody Therapeutics Product and Solutions
Table 49. Kyowa Hakko Kirin Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Xencor Corporate Information, Head Office, and Major Competitors
Table 51. Xencor Major Business
Table 52. Xencor Next Generation Antibody Therapeutics Product and Solutions
Table 53. Xencor Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Dyax Corp Corporate Information, Head Office, and Major Competitors
Table 55. Dyax Corp Major Business
Table 56. Dyax Corp Next Generation Antibody Therapeutics Product and Solutions
Table 57. Dyax Corp Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. Global Next Generation Antibody Therapeutics Revenue (USD Million) by Players (2019-2021)
Table 59. Global Next Generation Antibody Therapeutics Revenue Share by Players (2019-2021)
Table 60. Breakdown of Next Generation Antibody Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 61. Next Generation Antibody Therapeutics Players Head Office, Products and Services Provided
Table 62. Next Generation Antibody Therapeutics Mergers & Acquisitions in the Past Five Years
Table 63. Next Generation Antibody Therapeutics New Entrants and Expansion Plans
Table 64. Global Next Generation Antibody Therapeutics Revenue (USD Million) by Type (2016-2021)
Table 65. Global Next Generation Antibody Therapeutics Revenue Share by Type (2016-2021)
Table 66. Global Next Generation Antibody Therapeutics Revenue Forecast by Type (2021-2026)
Table 67. Global Next Generation Antibody Therapeutics Revenue by Application (2016-2021)
Table 68. Global Next Generation Antibody Therapeutics Revenue Forecast by Application (2021-2026)
Table 69. North America Next Generation Antibody Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 70. North America Next Generation Antibody Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 71. North America Next Generation Antibody Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 72. North America Next Generation Antibody Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 73. North America Next Generation Antibody Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 74. North America Next Generation Antibody Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 75. Europe Next Generation Antibody Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 76. Europe Next Generation Antibody Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 77. Europe Next Generation Antibody Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 78. Europe Next Generation Antibody Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 79. Europe Next Generation Antibody Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 80. Europe Next Generation Antibody Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 81. Asia-Pacific Next Generation Antibody Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 82. Asia-Pacific Next Generation Antibody Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 83. Asia-Pacific Next Generation Antibody Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 84. Asia-Pacific Next Generation Antibody Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 85. Asia-Pacific Next Generation Antibody Therapeutics Revenue by Region (2016-2021) & (USD Million)
Table 86. Asia-Pacific Next Generation Antibody Therapeutics Revenue by Region (2021-2026) & (USD Million)
Table 87. South America Next Generation Antibody Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 88. South America Next Generation Antibody Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 89. South America Next Generation Antibody Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 90. South America Next Generation Antibody Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 91. South America Next Generation Antibody Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 92. South America Next Generation Antibody Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 93. Middle East & Africa Next Generation Antibody Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 94. Middle East & Africa Next Generation Antibody Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 95. Middle East & Africa Next Generation Antibody Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 96. Middle East & Africa Next Generation Antibody Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 97. Middle East & Africa Next Generation Antibody Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 98. Middle East & Africa Next Generation Antibody Therapeutics Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Next Generation Antibody Therapeutics Picture
Figure 2. Global Next Generation Antibody Therapeutics Revenue Market Share by Type in 2020
Figure 3. Antibody Drug Conjugates (ADCs)
Figure 4. Bispecific Antibodies (BsAbs)
Figure 5. Fc Engineered Antibodies
Figure 6. Antibody Fragments and Antibody-Like Proteins (AF & ALPs)
Figure 7. Biosimilar Antibody (Ab) Products
Figure 8. Next Generation Antibody Therapeutics Revenue Market Share by Application in 2020
Figure 9. Hospitals Picture
Figure 10. Clinics Picture
Figure 11. Others Picture
Figure 12. Global Next Generation Antibody Therapeutics Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 13. Global Next Generation Antibody Therapeutics Revenue and Forecast (2016-2026) & (USD Million)
Figure 14. Global Next Generation Antibody Therapeutics Revenue Market Share by Region (2016-2026)
Figure 15. Global Next Generation Antibody Therapeutics Revenue Market Share by Region in 2020
Figure 16. North America Next Generation Antibody Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Europe Next Generation Antibody Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Asia-Pacific Next Generation Antibody Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. South America Next Generation Antibody Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Middle East and Africa Next Generation Antibody Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Next Generation Antibody Therapeutics Market Drivers
Figure 22. Next Generation Antibody Therapeutics Market Restraints
Figure 23. Next Generation Antibody Therapeutics Market Trends
Figure 24. Pfizer Recent Developments and Future Plans
Figure 25. Roche Recent Developments and Future Plans
Figure 26. Bristol-Myers Squibb Recent Developments and Future Plans
Figure 27. Amgen Recent Developments and Future Plans
Figure 28. AstraZeneca Recent Developments and Future Plans
Figure 29. Bayer Recent Developments and Future Plans
Figure 30. Takeda Pharmaceuticals Recent Developments and Future Plans
Figure 31. Biogen Recent Developments and Future Plans
Figure 32. Seattle Genetics Recent Developments and Future Plans
Figure 33. ImmunoGen Recent Developments and Future Plans
Figure 34. Kyowa Hakko Kirin Recent Developments and Future Plans
Figure 35. Xencor Recent Developments and Future Plans
Figure 36. Dyax Corp Recent Developments and Future Plans
Figure 37. Global Next Generation Antibody Therapeutics Revenue Share by Players in 2020
Figure 38. Next Generation Antibody Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 39. Global Top 3 Players Next Generation Antibody Therapeutics Revenue Market Share in 2020
Figure 40. Global Top 10 Players Next Generation Antibody Therapeutics Revenue Market Share in 2020
Figure 41. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 42. Global Next Generation Antibody Therapeutics Revenue Share by Type in 2020
Figure 43. Global Next Generation Antibody Therapeutics Market Share Forecast by Type (2021-2026)
Figure 44. Global Next Generation Antibody Therapeutics Revenue Share by Application in 2020
Figure 45. Global Next Generation Antibody Therapeutics Market Share Forecast by Application (2021-2026)
Figure 46. North America Next Generation Antibody Therapeutics Sales Market Share by Type (2016-2026)
Figure 47. North America Next Generation Antibody Therapeutics Sales Market Share by Application (2016-2026)
Figure 48. North America Next Generation Antibody Therapeutics Revenue Market Share by Country (2016-2026)
Figure 49. United States Next Generation Antibody Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. Canada Next Generation Antibody Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Mexico Next Generation Antibody Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Europe Next Generation Antibody Therapeutics Sales Market Share by Type (2016-2026)
Figure 53. Europe Next Generation Antibody Therapeutics Sales Market Share by Application (2016-2026)
Figure 54. Europe Next Generation Antibody Therapeutics Revenue Market Share by Country (2016-2026)
Figure 55. Germany Next Generation Antibody Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. France Next Generation Antibody Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. United Kingdom Next Generation Antibody Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Russia Next Generation Antibody Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Italy Next Generation Antibody Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Asia-Pacific Next Generation Antibody Therapeutics Sales Market Share by Type (2016-2026)
Figure 61. Asia-Pacific Next Generation Antibody Therapeutics Sales Market Share by Application (2016-2026)
Figure 62. Asia-Pacific Next Generation Antibody Therapeutics Revenue Market Share by Region (2016-2026)
Figure 63. China Next Generation Antibody Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Japan Next Generation Antibody Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. South Korea Next Generation Antibody Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. India Next Generation Antibody Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Southeast Asia Next Generation Antibody Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Australia Next Generation Antibody Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. South America Next Generation Antibody Therapeutics Sales Market Share by Type (2016-2026)
Figure 70. South America Next Generation Antibody Therapeutics Sales Market Share by Application (2016-2026)
Figure 71. South America Next Generation Antibody Therapeutics Revenue Market Share by Country (2016-2026)
Figure 72. Brazil Next Generation Antibody Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Argentina Next Generation Antibody Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Middle East and Africa Next Generation Antibody Therapeutics Sales Market Share by Type (2016-2026)
Figure 75. Middle East and Africa Next Generation Antibody Therapeutics Sales Market Share by Application (2016-2026)
Figure 76. Middle East and Africa Next Generation Antibody Therapeutics Revenue Market Share by Country (2016-2026)
Figure 77. Turkey Next Generation Antibody Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Saudi Arabia Next Generation Antibody Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. UAE Next Generation Antibody Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. Methodology
Figure 81. Research Process and Data Source
Buy
